Member Info for Tillywhiz

Stock has been anchored to 1.6 for weeks

We require vol

More importantly all invested await the next update on CAR T …

Cogs will be turning

Prevail ain’t no naive muppets , they are a professional organisation who backed Hemos science & tossed a wedge in a lot higher than current stock price ,

I’m sure Vlad & Prevail are investigating all potential avenues for the benefit of Hemo & stockholders including Prevail .

Noted by Prevail in Sept RNS 👍

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."

News will flow & the stock will re rate imo

Have a superb weekend all invested & re group Tuesday morn

Certainly a buy after checking imo

Vwap 1.556 currently

ticked up after it was printed , a 50k kipper is a decent size

Like I said will check shorts later on , to see if closed out .

Actually looking at prices etc

Looks like a buy

I will check the shorts later & see if a change , if it was the short has been open months & made nothing , oh dear .

Volume has been very thin last few sessions

Probably taken most of day to fill this order in this thin vol & looks like a sell

Date Time Trade Prc Volume Buy/Sell Bid Ask Value

03-May-24 15:48:41 1.565 3,250,000 Unknown* 1.526 1.60 50.86k O

Very little if not in debt #margin call sniffing

The buy price to close out is exactly what the short was opened at 1.6

& with the cost to borrow high & opened over 6 weeks ago likely in red ,

Oh dear what shame ,

Great input Pump , your afternoons must be full of excitement.

Request for a sample report to understand more about the Aplastic Anemia pipeline development activities @ https://www.delveinsight.com/sample-request/aplastic-anemia-market

Aplastic Anemia Therapeutics Assessment

Major key companies are working proactively in the Aplastic Anemia Therapeutics market to develop novel therapies which will drive the Aplastic Anemia treatment markets in the upcoming years are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and Many Others.

Learn more about the emerging Aplastic Anemia therapies & key companies @ https://www.delveinsight.com/sample-request/aplastic-anemia-market

End

This segment gives a thorough detail of the Aplastic Anemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Aplastic Anemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Aplastic Anemia market in 7MM is expected to witness a major change in the study period 2020-2034.

Aplastic Anemia Epidemiology

The Aplastic Anemia epidemiology section provides insights into the historical and current Aplastic Anemia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Aplastic Anemia market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Aplastic Anemia Epidemiology @ Aplastic Anemia Market Dynamics

Aplastic Anemia Drugs Uptake

This section focuses on the uptake rate of the potential Aplastic Anemia drugs recently launched in the Aplastic Anemia market or expected to be launched in 2020-2034. The analysis covers the Aplastic Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Aplastic Anemia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Aplastic Anemia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Aplastic Anemia Pipeline Development Activities

The Aplastic Anemia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Aplastic Anemia key players involved in developing targeted therapeutics.

Con’t

Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin (r-ATG) and Cyclosporine a (CsA) in East-Asian Patients With Treatment Naive Severe Aplastic Anemia (REACTS). *On August 2023, Kyowa Kirin Co., Ltd announced results of a Long Term Follow-up Observational Study after Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia.

Aplastic Anemia Overview

Aplastic anemia is a rare but serious blood disorder characterized by the inability of the bone marrow to produce enough blood cells. This deficiency results in a decrease in red blood cells, white blood cells, and platelets, leading to symptoms such as fatigue, weakness, frequent infections, and easy bruising or bleeding. The condition can be acquired due to exposure to toxins, certain medications, infections, or autoimmune disorders, or it can be inherited. Diagnosis typically involves blood tests, bone marrow biopsy, and other specialized tests. Treatment options vary depending on the severity and cause of the aplastic anemia but may include blood transfusions, medications to stimulate blood cell production, immunosuppressive therapy, or bone marrow transplant. Close monitoring and ongoing medical care are essential for managing the condition and minimizing complications.

Learn more about Aplastic Anemia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/aplastic-anemia-market

Aplastic Anemia Market

The Aplastic Anemia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Aplastic Anemia market trends by analyzing the impact of current Aplastic Anemia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

Con’t ….

Full Article 👍

Aplastic Anemia Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies, Companies & Growth Analysis Report by DelveInsight

M2 Communications

2nd May 14:35

Leading Aplastic Anemia companies working in the market are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and Many Others. *Leading Aplastic Anemia companies working in the market are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell,...

Leading Aplastic Anemia companies working in the market are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and Many Others.

(Albany, USA) DelveInsight's "Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Aplastic Anemia, historical and forecasted epidemiology as well as the Aplastic Anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Aplastic Anemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Aplastic Anemia market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Aplastic Anemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Aplastic Anemia market.

Request for a Free Sample Report @ Aplastic Anemia Market Forecast

Some facts of the Aplastic Anemia Market Report are:*According to DelveInsight, Aplastic Anemia market size is expected to grow at a decent CAGR by 2034. *In the 7MM, United States accounted for the largest Aplastic Anemia Market Size in 2023, with approximately USD ~190 million. *Leading Aplastic Anemia companies working in the market are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and Many Others. *Key Aplastic Anemia Therapies expected to launch in the market are PF-06462700, REGN7257, BL-8040, and Others. *On April 2024, Rocket Pharmaceuticals announced results of a Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects with Fanconi Anemia Subtype A. *On March 2024, Regeneron Pharmaceuticals announced results of a Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy. *On February 2024, Novartis announced results of a Non-randomized, Open Label, Multi-center,

Con’t…

Afternoon all

Hemo mentioned on Ortex will post full article if anyone fancy’s a read with a cuppa 👍

Aplastic Anemia Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies, Companies & ...

World News

2nd May 13:04

"Aplastic Anemia Market" Leading Aplastic Anemia companies working in the market are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida

Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and Many Others. (Albany, USA) DelveInsight's "Aplastic read full story

Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2034

Morning all

Volume has ticked up this morning & needed to after last 2 weeks thin vol

I suspect a blue north finish today after touching 1.52

Poor with the potential

Let’s see what coming weeks bring

Exactly HT -

Company published results & Proactive investors are an investment organisation that highlight possible investments

& there current status etc etc & Vlad is at the spearhead of a science company doing great work & agreed to the interview to project Hemo & a potential investment & Proactive print the interview & facts - simple as they do with many companies every month .

Shorts / stock on loan

( which I only post to assist the invested for info purposes )

4.2 million opened @around 1.6 after the placement will be paying the cost to borrow daily so 6 weeks in , likely on a loss & sweating if a positive RNS drops .

The impatient sell & the small time Shorters try & fleece a few quid ,

However imo the investors with patience will be rewarded & Prevail certainly saw the potential otherwise why invest & get involved …

Noted by Prevail in Sept RNS

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."

Let’s see what next few months bring

Morning all invested

Cogs will be turning

Prevail ain’t no naive muppets , they are a professional organisation who backed Hemos science & tossed a wedge in a lot higher than current stock price ,

I’m sure Vlad & Prevail are investigating all potential avenues for the benefit of Hemo & stockholders including Prevail .

Noted by Prevail in Sept RNS 👍

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."

Stock needs volume & positive news will bring volume & stock re rate imo .

To note -

Stock on loan / shorts

Current 4.3 million

a 200 k short was opened last week , I would guess a chancer hoping for bad news within the results - didn’t happen

& a 4.2 million short was opened 2 days after placement news @1.62

Currently underwater - unlucky 👎

So i am sceptical on any stock & any forums with negativity been posted with recent shorts opened , very risky in Hemo’s current position imo

Hemo are clinical & working with Prevail on CAR T 👍

With CBR & CDX cooking 👍

Good products will attract financial pharmas once news is confirmed. Imo 👍👍

Let’s see what next few months bring

Hulver - good post ,

Prevail ain’t no naive muppets , they are a professional organisation who backed Hemos science & tossed a wedge in a lot higher than current stock price ,

I’m sure Vlad & Prevail are investigating all potential avenues for the benefit of Hemo & stockholders including Prevail .

Noted by Prevail in Sept RNS

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."

Let’s see what next few months bring

HT - good point & did think similar ( or hope )

Cyrox - that got a chuckle 👍

Closing price 1.59 - 1%+

Vol 5.4 million - low

Let’s see what coming weeks / months bring

A lot of disgruntled investors on here of late

Stock price has been stuck between 1.55 @ 1.7 for weeks since placement

Volume is very low of late

3 million today

The stock certainly won’t motor north with thin volume , & purely trading water until news arrives .

However will motor north when further news on clinical is announced or a pharma deal with help from Prevail , imo

To note -

Stock on loan / shorts

Current 4.3 million

a 200 k short was opened Tuesday , I would guess a chancer hoping for bad news within the results

& a 4.2 million short was opened 2 days after placement news @1.62

So i am sceptical on any stock & any forums with negativity been posted with recent shorts opened , very risky in Hemo’s current position imo

Hemo are clinical & working with Prevail on CAR T

With CBR & CDX cooking

Good products will attract financial pharmas once news is confirmed. Imo

Morning all invested

RNS - does what it says on the tin

Not a stock mover .

Highlights the science continues development -

CAR T clinical

Underpinned by Prevail

Cash in the bank

CBR & CDX plenty of info on these developments & huge potential

Let’s see what next few months bring - I’m sure Vlad & Prevail aren’t sat twiddling their thumbs

All invested have choices - buy - hold - sell

I’m very content to let all Hemo science unfold & stock re rate - especially from current levels

Dry powder level imo the science is developing & a nice juicy pharma deal would suffice .

Morning All

Stock continues to fluctuate between 1.6- 1.7 until volume increases or an RNS drops …

Plenty of bed & isa trades over recent sessions .

Hemo is in a very strong position vs potential returns imo .especially from current levels ,

Re - read recent RNS & Vlads interview …

cash raised -

- clinical on CAR T -

- zero debt

- underpinned by prevail

- multi pronged science - CBR , CDX

Let’s see what next month brings - Vlads certainly quiet , perhaps at present busy turning those CAR T cogs with Prevail no doubt & any whiff of a pharma deal / partnership & the stock price will be Broadsided imo

The science continues

morning all actual stockholders

second that ****nalles great work jaygee , & shows there are mining pans simmering in the shadows of the war .

all invested await a whiff of potential asset sale .

this board is almost unreadable of late half a dozen crackpots goading any investor who actually mentions eua & arguing over war situation & political agenda ,

yet probably the nearest to any military action any of them got was level 3 on cod 👎

even septic lil is bored with these reincarnated keyboard bots .

green energy boom / asset sale of precious metals vs war situation / political battlefield

Closing price 1.664

Vol 11.6 million

Big Friday RNS would suffice 👍